Q3304849 (Q3304849): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy., translated_summary) |
||||||||||||||
| Property / summary | |||||||||||||||
Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy. (English) | |||||||||||||||
| Property / summary: Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy. (English) / qualifier | |||||||||||||||
point in time: 24 October 2021
| |||||||||||||||
Revision as of 17:52, 24 October 2021
Project Q3304849 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3304849 in Germany |
Statements
656,244.0 Euro
0 references
820,305.0 Euro
0 references
80.0 percent
0 references
28 September 2017
0 references
30 June 2023
0 references
Miltenyi Biotec GmbH Niederlassung Teterow
0 references
17166 - Teterow
0 references
Entwicklung einer Vorhersagemöglichkeit für den Nutzen der Apherese bei Multiple Sklerose (MS) Patienten im akuten Schub. Dazu werden diagnostische Kits entwickelt, die Responder von Non-Respondern für die Plamapherese-Therapie unterscheiden. (German)
0 references
Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy. (English)
24 October 2021
0 references
Identifiers
DE_TEMPORARY_7634
0 references